{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:23:47Z","timestamp":1775255027776,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000954","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T16:47:03Z","timestamp":1069346823000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Janet","family":"Pope","sequence":"first","affiliation":[{"name":"University of Western Ontario; Dept of Medicine and Epidemiology and Biostatistics; St. Joseph's Health Care 268 Grosvenor St London Ontario Canada N6A 4V2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Fenlon","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre, University of Western Ontario; Department of Surgery; 375 South Street, Suite N345 London Ontario Canada N6A 4G5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Thompson","sequence":"additional","affiliation":[{"name":"St Joseph's Health Care; Department of Rheumatology; 268 Grosvenor Street London Ontario Canada N6A 4V2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"University of Ottawa; Institute of Population Health; 1 Stewart St. Room 312 Ottawa Ontario Canada K1N 6N5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Furst","sequence":"additional","affiliation":[{"name":"Virginia Mason Research Center; 10000 Seneca Street Seattle WA 98101 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute; Cardiovascular Research Reference Centre; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Silman","sequence":"additional","affiliation":[{"name":"University of Manchester; ARC Epidemiology Research Unit; Stopford Building, Oxford Road Manchester UK M13 9PT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1998,4,27]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD000954-BIB0001|cit1","first-page":"260","article-title":"[Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases]. [French]","volume":"137","author":"Cadranel","year":"1986","journal-title":"Annales de Medecine Interne"},{"issue":"1","key":"10.1002\/14651858.CD000954-BIB0002|cit2","first-page":"77","article-title":"Ketanserin versus nifedipine in secondary Raynaud's phenomenon","volume":"16","author":"Kirch","year":"1987","journal-title":"VASA"},{"issue":"9","key":"10.1002\/14651858.CD000954-BIB0003|cit3","first-page":"659","article-title":"Tauchmannova H.Zitnan D. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial","volume":"11","author":"Lukac","year":"1985","journal-title":"Drugs Under Experimental & Clinical Research"},{"issue":"2","key":"10.1002\/14651858.CD000954-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.1989.tb07791.x","article-title":"Dujardin P.Fraitag B. Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial","volume":"120","author":"Ortonne","year":"1989","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD000954-BIB0005|cit5","first-page":"313","article-title":"The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study","volume":"6","author":"Wal","year":"1987","journal-title":"International Angiology"},{"issue":"1","key":"10.1002\/14651858.CD000954-BIB0006|cit6","first-page":"19","article-title":"Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study","volume":"7","author":"Arneklo-Nobin","year":"1988","journal-title":"International Angiology"},{"issue":"7","key":"10.1002\/14651858.CD000954-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/000331978904000705","article-title":"Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon","volume":"40","author":"Arosio","year":"1989","journal-title":"Angiology"},{"issue":"5","key":"10.1002\/14651858.CD000954-BIB0008|cit8","first-page":"408","article-title":"Efficacy of ketanserin in the therapy of Raynaud's phenomenon: thermometric data","volume":"42","author":"Arosio","year":"1991","journal-title":"Angiology - The Journal of Vascular Diseases"},{"issue":"1","key":"10.1002\/14651858.CD000954-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00404349","article-title":"Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study","volume":"279","author":"Baart de la Faille","year":"1986","journal-title":"Archives of Dermatological Research"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD000954-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/00005344-198706103-00007","article-title":"Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's disease","volume":"10","author":"Brouwer","year":"1987","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD000954-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/000331979104200607","article-title":"Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon","volume":"42","author":"Caputi","year":"1991","journal-title":"Angiology"},{"issue":"2","key":"10.1002\/14651858.CD000954-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/000331978904000206","article-title":"Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon","volume":"40","author":"Codella","year":"1989","journal-title":"Angiology"},{"issue":"3","key":"10.1002\/14651858.CD000954-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0002-9343(89)80148-2","article-title":"International study of ketanserin in Raynaud's phenomenon","volume":"87","author":"Coffman","year":"1989","journal-title":"American Journal of Medicine"},{"issue":"36","key":"10.1002\/14651858.CD000954-BIB0014|cit14","first-page":"1322","article-title":"Double-blind clinical evaluation of naftidrofuryl in Raynaud's phenomenon","volume":"69","author":"Davinroy","year":"1993","journal-title":"Semaine des Hopitaux"},{"issue":"6","key":"10.1002\/14651858.CD000954-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.1988.tb03498.x","article-title":"Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma","volume":"119","author":"Engelhart","year":"1988","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD000954-BIB0016|cit16","first-page":"87","article-title":"Medical treatment in Raynaud's disease","volume":"465","author":"Hansteen","year":"1976","journal-title":"Acta Chirurgica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD000954-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/03009748909099925","article-title":"Ketanserin: An Effective Treatment Regimen for Digital Ischaemia in Systemic Sclerosis","volume":"18","author":"Klimiuk","year":"1989","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD000954-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00540954","article-title":"Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy","volume":"34","author":"Kunnen","year":"1988","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000954-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1097\/00005344-198500077-00028","article-title":"Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon","volume":"7 Suppl 7","author":"Longstaff","year":"1985","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD000954-BIB0020|cit20","first-page":"869","article-title":"Long-term ketanserin treatment in patients with systemic sclerosis in Raynaud's phenomenon","volume":"50","author":"Lukac","year":"1991","journal-title":"Current Therapeutic Research"},{"issue":"4","key":"10.1002\/14651858.CD000954-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00561375","article-title":"Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon","volume":"35","author":"Marasini","year":"1988","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000954-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2125.1990.tb05450.x","article-title":"Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon","volume":"30","author":"Marasini","year":"1990","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6445","key":"10.1002\/14651858.CD000954-BIB0023|cit23","first-page":"577","article-title":"Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders","volume":"289","author":"Roald","year":"1984","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"2","key":"10.1002\/14651858.CD000954-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/art.1780270204","article-title":"Treatment of Raynaud's Phenomenon with Ketanserin, a Selective Antagonist of the Serotonin2 (5-HT2) Receptor","volume":"27","author":"Seibold","year":"1984","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD000954-BIB0025|cit25","first-page":"249","article-title":"Ketanserin and capillary flow in Raynaud's phenomenon","volume":"9","author":"Tooke","year":"1990","journal-title":"International Journal of Microcirculation: Clinical & Experimental"},{"key":"10.1002\/14651858.CD000954-BIB0026|cit26","first-page":"657","article-title":"Quantitative study of the effects of ketanserin in patients with primary Raynaud's phenomenon","volume":"2","author":"Wal","year":"1985","journal-title":"Microcirculation, Endothelium, and Lymphatics"},{"key":"10.1002\/14651858.CD000954-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"ACR Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD000954-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD000954-BIB0029|cit29","first-page":"21","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD000954-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000954-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00845268","article-title":"Behavioral treatment of Raynaud's phenomenon in scleroderma","volume":"7","author":"Freedman","year":"1984","journal-title":"Journal of Behavioral Medicine"},{"key":"10.1002\/14651858.CD000954-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD000954-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00002281-199411000-00013","article-title":"Raynaud's phenomenon and vascular disease in scleroderma","volume":"6","author":"Kahaleh","year":"1994","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD000954-BIB0034|cit34","first-page":"485","article-title":"Raynaud's Phenomenon: A Prosposal for Classification","volume":"10","author":"LeRoy","year":"1992","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD000954-BIB0035|cit35","unstructured":"Medsger TA JR Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis McCarty DJ Arthritis and Allied Conditions 10 Philadelphia Lea & Febiger"},{"key":"10.1002\/14651858.CD000954-BIB0036|cit36","first-page":"90","volume-title":"Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine","author":"Petitti","year":"1994"},{"key":"10.1002\/14651858.CD000954-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0002-9343(72)90020-4","article-title":"Studies of Endogenous Catecholamines in Patients with Raynaud's Phenomenon Secondary to Progressive Systemic Sclerosis (Scleroderma)","volume":"52","author":"Sapira","year":"1972","journal-title":"The American Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD000954\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:02:48Z","timestamp":1775250168000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000954"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[1998,4,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000954","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4,27]]}}}